(Q34444824)

2 August 2017

1 reference

title

Evidence for cardioprotective, renoprotective, and vasculoprotective effects of vasopeptidase inhibitors in disease (English)

1 reference

2 August 2017

5

Johnston CI

1 reference

2 August 2017

6

Burrell LM

1 reference

2 August 2017

Kubota E

1

1 reference

2 August 2017

Dean RG

series ordinal

2

1 reference

2 August 2017

Hubner RA

series ordinal

3

1 reference

2 August 2017

Balding LC

series ordinal

4

1 reference

2 August 2017

language of work or name

1 reference

1 December 2001

1 reference

Current Hypertension Reports

2 August 2017

1 reference

2 August 2017

3 Suppl 2

1 reference

2 August 2017

S31-3

1 reference

https://scigraph.springernature.com/pub.10.1007/s11906-001-0105-8

2 August 2017

0 references

cites work

Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis.

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11906-001-0105-8

Vasopeptidase Inhibition Prevents Endothelial Dysfunction of Resistance Arteries in Salt-Sensitive Hypertension in Comparison With Single ACE Inhibition.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11906-001-0105-8

Antihypertensive and antihypertrophic effects of omapatrilat in SHR

21 January 2018

1 reference

12 December 2020

Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial

1 reference

12 December 2020

Vasopeptidase inhibition: a new concept in blood pressure management

1 reference

12 December 2020

Interaction between atrial natriuretic peptide and the renin angiotensin aldosterone system. Endogenous antagonists

1 reference

12 December 2020

Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats

1 reference

12 December 2020

Omapatrilat, a dual angiotensin-converting enzyme and neutral endopeptidase inhibitor, prevents fatty streak deposit in apolipoprotein E-deficient mice.

1 reference

12 December 2020

Protective effects of CGS 30440, a combined angiotensin-converting enzyme inhibitor and neutral endopeptidase inhibitor, in a model of chronic renal failure.

1 reference

12 December 2020

New hormonal blockade strategies in cardiovascular disease.

1 reference

12 December 2020

Emerging treatments for hypertension: potential role for vasopeptidase inhibition

1 reference

12 December 2020

Optimizing treatment of hypertension in patients with diabetes

1 reference

12 December 2020

Comparison of a vasopeptidase inhibitor with neutral endopeptidase and angiotensin-converting enzyme inhibitors on bradykinin metabolism in the rat coronary bed.

1 reference

12 December 2020

Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology

1 reference

12 December 2020

Reversal of cardiac hypertrophy and fibrosis by S21402, a dual inhibitor of neutral endopeptidase and angiotensin converting enzyme in SHRs

1 reference

12 December 2020

1 reference

12 December 2020

Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril

1 reference

12 December 2020

Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus

1 reference

12 December 2020

Beneficial renal and cardiac effects of vasopeptidase inhibition with S21402 in heart failure

1 reference

12 December 2020

10.1007/S11906-001-0105-8

Identifiers

DOI

1 reference

Dimensions Publication ID

2 August 2017

0 references

1 reference